When a company deploys a poison pill against you, most investors take the hint. Carl Icahn is not most investors.

The legendary activist shareholder dramatically increased his stake in Monro, Inc. (MNRO) during the fourth quarter, continuing to buy shares even after the auto repair chain adopted takeover defenses explicitly aimed at blocking his growing influence. According to his latest 13F filing, Icahn boosted his position by 247% in the quarter, jumping from 1.46 million shares to over 5.07 million shares as of December 31.

That stake is now worth approximately $102 million, making Icahn the company's largest shareholder by a comfortable margin.

The Poison Pill Didn't Work as Intended

Monro adopted its shareholder rights plan in November after Icahn rapidly assembled a position approaching 17% of the company. The poison pill was designed to prevent any investor from crossing the 17.5% threshold without board approval, effectively capping Icahn's ability to take control.

But Icahn kept buying anyway. His continued accumulation throughout the fourth quarter shows he's not discouraged by the defensive maneuver. If anything, it signals conviction that Monro is undervalued and that he's prepared to push for changes.

What Comes Next?

Icahn has a well-documented playbook when it comes to automotive aftermarket businesses. He's previously targeted companies like Pep Boys and Federal-Mogul, typically pushing for operational improvements, strategic shifts, or outright sales to unlock shareholder value.

The fact that he's still accumulating shares despite Monro's resistance suggests this isn't a passive investment. The strategic tension between Icahn and company leadership appears to be escalating, and investors should expect fireworks.

With Icahn now firmly entrenched as Monro's dominant shareholder and showing no signs of backing off, the question isn't whether he'll push for change. It's when and how aggressive that push will be.